Trials / Completed
CompletedNCT01311349
Study Evaluating Local Susceptibility Patterns Associated With Tigecycline in Comparison to Other Antibiotics
Evaluation of the Antimicrobial Activity In Vitro of Tigecycline in Comparison to Other Broad Spectrum Antibiotics in Isolates Collected From Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,575 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Various bacterial organisms will be tested in order to compile information regarding the effectiveness of tigecycline against certain bacteria seen in local communities.
Detailed description
This is a prospective, microbiologic in vitro evaluation which will study the susceptibility of tigecycline in disk diffusion on clinical bacterial isolates collected from inpatients and outpatients. Fourteen hospital centers participated in the program. In vitro efficacy of tigecycline will be determined through the in vitro disk diffusion activity, using FDA breakpoints.
Conditions
Timeline
- Start date
- 2005-12-01
- Completion
- 2006-09-01
- First posted
- 2011-03-09
- Last updated
- 2011-03-09
Source: ClinicalTrials.gov record NCT01311349. Inclusion in this directory is not an endorsement.